Lutris Pharma Secures $30 Million to Enhance EGFR Inhibitor Treatments

Lutris Pharma, an Israel-based clinical stage biopharmaceutical company, has secured a $30 million investment to continue developing LUT014, a topical gel designed to combat acneiform rashes induced by EGFR inhibitors (EGFRi). This investment round was led by new investor Columbus Venture Partners and existing investors Pontifax Venture Capital, Peregrine Ventures, and aMoon Fund. These rashes are significant dose-limiting toxicities associated with EGFRi cancer treatments, often leading to the premature discontinuation of effective cancer therapies. By mitigating this common side effect, LUT014 holds the potential to improve both treatment adherence and patients' quality of life. Chief Executive Officer Noa Shelach emphasized the critical nature of this financing, which will support ongoing clinical trials and help address a substantial unmet need in cancer treatment. With successful patient enrollment in their phase 2 trial, the company anticipates sharing top-line results in 2025. The development promises a paradigm shift in how EGFRi therapies can be managed, potentially transforming them into more sustainable treatment options for cancer patients.